Cargando…

Enhancing cancer clonality analysis with integrative genomics

INTRODUCTION: It is understood that cancer is a clonal disease initiated by a single cell, and that metastasis, which is the spread of cancer from the primary site, is also initiated by a single cell. The seemingly natural capability of cancer to adapt dynamically in a Darwinian manner is a primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Peterson, Erich A, Bauer, Michael A, Chavan, Shweta S, Ashby, Cody, Weinhold, Niels, Heuck, Christoph J, Morgan, Gareth J, Johann, Donald J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597064/
https://www.ncbi.nlm.nih.gov/pubmed/26424171
http://dx.doi.org/10.1186/1471-2105-16-S13-S7
_version_ 1782393858947022848
author Peterson, Erich A
Bauer, Michael A
Chavan, Shweta S
Ashby, Cody
Weinhold, Niels
Heuck, Christoph J
Morgan, Gareth J
Johann, Donald J
author_facet Peterson, Erich A
Bauer, Michael A
Chavan, Shweta S
Ashby, Cody
Weinhold, Niels
Heuck, Christoph J
Morgan, Gareth J
Johann, Donald J
author_sort Peterson, Erich A
collection PubMed
description INTRODUCTION: It is understood that cancer is a clonal disease initiated by a single cell, and that metastasis, which is the spread of cancer from the primary site, is also initiated by a single cell. The seemingly natural capability of cancer to adapt dynamically in a Darwinian manner is a primary reason for therapeutic failures. Survival advantages may be induced by cancer therapies and also occur as a result of inherent cell and microenvironmental factors. The selected "more fit" clones outmatch their competition and then become dominant in the tumor via propagation of progeny. This clonal expansion leads to relapse, therapeutic resistance and eventually death. The goal of this study is to develop and demonstrate a more detailed clonality approach by utilizing integrative genomics. METHODS: Patient tumor samples were profiled by Whole Exome Sequencing (WES) and RNA-seq on an Illumina HiSeq 2500 and methylation profiling was performed on the Illumina Infinium 450K array. STAR and the Haplotype Caller were used for RNA-seq processing. Custom approaches were used for the integration of the multi-omic datasets. RESULTS: Reported are major enhancements to CloneViz, which now provides capabilities enabling a formal tumor multi-dimensional clonality analysis by integrating: i) DNA mutations, ii) RNA expressed mutations, and iii) DNA methylation data. RNA and DNA methylation integration were not previously possible, by CloneViz (previous version) or any other clonality method to date. This new approach, named iCloneViz (integrated CloneViz) employs visualization and quantitative methods, revealing an integrative genomic mutational dissection and traceability (DNA, RNA, epigenetics) thru the different layers of molecular structures. CONCLUSION: The iCloneViz approach can be used for analysis of clonal evolution and mutational dynamics of multi-omic data sets. Revealing tumor clonal complexity in an integrative and quantitative manner facilitates improved mutational characterization, understanding, and therapeutic assignments.
format Online
Article
Text
id pubmed-4597064
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45970642015-10-08 Enhancing cancer clonality analysis with integrative genomics Peterson, Erich A Bauer, Michael A Chavan, Shweta S Ashby, Cody Weinhold, Niels Heuck, Christoph J Morgan, Gareth J Johann, Donald J BMC Bioinformatics Proceedings INTRODUCTION: It is understood that cancer is a clonal disease initiated by a single cell, and that metastasis, which is the spread of cancer from the primary site, is also initiated by a single cell. The seemingly natural capability of cancer to adapt dynamically in a Darwinian manner is a primary reason for therapeutic failures. Survival advantages may be induced by cancer therapies and also occur as a result of inherent cell and microenvironmental factors. The selected "more fit" clones outmatch their competition and then become dominant in the tumor via propagation of progeny. This clonal expansion leads to relapse, therapeutic resistance and eventually death. The goal of this study is to develop and demonstrate a more detailed clonality approach by utilizing integrative genomics. METHODS: Patient tumor samples were profiled by Whole Exome Sequencing (WES) and RNA-seq on an Illumina HiSeq 2500 and methylation profiling was performed on the Illumina Infinium 450K array. STAR and the Haplotype Caller were used for RNA-seq processing. Custom approaches were used for the integration of the multi-omic datasets. RESULTS: Reported are major enhancements to CloneViz, which now provides capabilities enabling a formal tumor multi-dimensional clonality analysis by integrating: i) DNA mutations, ii) RNA expressed mutations, and iii) DNA methylation data. RNA and DNA methylation integration were not previously possible, by CloneViz (previous version) or any other clonality method to date. This new approach, named iCloneViz (integrated CloneViz) employs visualization and quantitative methods, revealing an integrative genomic mutational dissection and traceability (DNA, RNA, epigenetics) thru the different layers of molecular structures. CONCLUSION: The iCloneViz approach can be used for analysis of clonal evolution and mutational dynamics of multi-omic data sets. Revealing tumor clonal complexity in an integrative and quantitative manner facilitates improved mutational characterization, understanding, and therapeutic assignments. BioMed Central 2015-09-25 /pmc/articles/PMC4597064/ /pubmed/26424171 http://dx.doi.org/10.1186/1471-2105-16-S13-S7 Text en Copyright © 2015 Peterson et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Proceedings
Peterson, Erich A
Bauer, Michael A
Chavan, Shweta S
Ashby, Cody
Weinhold, Niels
Heuck, Christoph J
Morgan, Gareth J
Johann, Donald J
Enhancing cancer clonality analysis with integrative genomics
title Enhancing cancer clonality analysis with integrative genomics
title_full Enhancing cancer clonality analysis with integrative genomics
title_fullStr Enhancing cancer clonality analysis with integrative genomics
title_full_unstemmed Enhancing cancer clonality analysis with integrative genomics
title_short Enhancing cancer clonality analysis with integrative genomics
title_sort enhancing cancer clonality analysis with integrative genomics
topic Proceedings
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597064/
https://www.ncbi.nlm.nih.gov/pubmed/26424171
http://dx.doi.org/10.1186/1471-2105-16-S13-S7
work_keys_str_mv AT petersonericha enhancingcancerclonalityanalysiswithintegrativegenomics
AT bauermichaela enhancingcancerclonalityanalysiswithintegrativegenomics
AT chavanshwetas enhancingcancerclonalityanalysiswithintegrativegenomics
AT ashbycody enhancingcancerclonalityanalysiswithintegrativegenomics
AT weinholdniels enhancingcancerclonalityanalysiswithintegrativegenomics
AT heuckchristophj enhancingcancerclonalityanalysiswithintegrativegenomics
AT morgangarethj enhancingcancerclonalityanalysiswithintegrativegenomics
AT johanndonaldj enhancingcancerclonalityanalysiswithintegrativegenomics